Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs

Spleen tyrosine kinase (SYK) is a cytosolic nonreceptor protein tyrosine kinase that mediates key signal transduction pathways following the activation of immune cell receptors. SYK regulates cellular events induced by the B‐cell receptor and Fc receptors with high intrinsic activity. Furthermore, S...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The FEBS journal 2016-10, Vol.283 (19), p.3613-3625
Hauptverfasser: Lee, Sang Jae, Choi, Jang‐Sik, Han, Byeong‐Gu, Kim, Hyoun Sook, Song, Ho‐Juhn, Lee, Jaekyoo, Nam, Seungyoon, Goh, Sung‐Ho, Kim, Jung‐Ho, Koh, Jong Sung, Lee, Byung Il
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3625
container_issue 19
container_start_page 3613
container_title The FEBS journal
container_volume 283
creator Lee, Sang Jae
Choi, Jang‐Sik
Han, Byeong‐Gu
Kim, Hyoun Sook
Song, Ho‐Juhn
Lee, Jaekyoo
Nam, Seungyoon
Goh, Sung‐Ho
Kim, Jung‐Ho
Koh, Jong Sung
Lee, Byung Il
description Spleen tyrosine kinase (SYK) is a cytosolic nonreceptor protein tyrosine kinase that mediates key signal transduction pathways following the activation of immune cell receptors. SYK regulates cellular events induced by the B‐cell receptor and Fc receptors with high intrinsic activity. Furthermore, SYK has been regarded as an attractive target for the treatment of autoimmune diseases and cancers. Here, we report the crystal structures of SYK in complex with seven newly developed inhibitors (G206, G207, O178, O194, O259, O272, and O282) to provide structural insights into which substituents of the inhibitors and binding regions of SYK are essential for lead compound optimization. Our kinase inhibitors exhibited high inhibitory activities against SYK, with half‐maximal inhibitory concentrations (IC50) of approximately 0.7–33 nm, but they showed dissimilar inhibitory activities against KDR, RET, JAK2, JAK3, and FLT3. Among the seven SYK inhibitors, O272 and O282 exhibited highly specific inhibitions against SYK, whereas O194 exhibited strong inhibition of both SYK and FLT3. Three inhibitors (G206, G207, and O178) more efficiently inhibited FLT3 while still substantially inhibiting SYK activity. The binding mode analysis suggested that a highly selective SYK inhibitor can be developed by optimizing the functional groups that facilitate direct interactions with Asn499. Database The atomic coordinates and structure factors for human SYK are in the Protein Data Bank under accession codes 4XG2 (inhibitor‐free form), 4XG3 (G206), 4XG4 (G207), 5GHV (O178), 4XG6 (O194), 4XG7 (O259), 4XG8 (O272), and 4XG9 (O282). Spleen tyrosine kinase (SYK) has been regarded as an attractive target for the treatment of autoimmune diseases and cancers. Our crystal structures of SYK in complex with seven newly developed inhibitors can provide structural insights into which substituents (a, b, and c) of the inhibitors, and binding regions of SYK are essential for lead compound optimization.
doi_str_mv 10.1111/febs.13831
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1837308493</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1837308493</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5371-f088863d27c4dce632fa272fa03993319c96cbd20f27440f168b35a97ab525f3</originalsourceid><addsrcrecordid>eNqNkc1PFDEYhxuiEUQv_AGmiRdDstDPaccbbEBNSDzAwduk02nZ4my79O2Ae-Q_t-viHjgY26Qfb588Sd8fQkeUnNA6Tr3r4YRyzekeOqBKsJlopH61O4sf--gtwB0hXIq2fYP2mZJEtLw5QE_zvIZiRgwlT7ZM2QFOHsNqdC7iss4JQnT4Z4gGHA4R27Ssb7_wYygLHNODG2t1EfpQUobPO43ZlCHcLgpgnzIeXL3EjdrEEqyJ1tVinm7hHXrtzQju_fN-iG4uL27mX2dX3798m59dzazkis480Vo3fGDKisG6hjNvmKoL4W3LOW1t29h-YMQzJQTxtNE9l6ZVppdMen6IPm21q5zuJwelWwawbhxNdGmCjmquONG1K_-DyjqpVBX9-AK9S1OO9R-VEkIrqhit1PGWsrWdkJ3vVjksTV53lHSbCLtNhN2fCCv84Vk59Us37NC_mVWAboHHMLr1P1Td5cX59Vb6G1d6p9E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1844871721</pqid></control><display><type>article</type><title>Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs</title><source>MEDLINE</source><source>Wiley Free Archive</source><source>Wiley Blackwell Single Titles</source><source>Free Full-Text Journals in Chemistry</source><creator>Lee, Sang Jae ; Choi, Jang‐Sik ; Han, Byeong‐Gu ; Kim, Hyoun Sook ; Song, Ho‐Juhn ; Lee, Jaekyoo ; Nam, Seungyoon ; Goh, Sung‐Ho ; Kim, Jung‐Ho ; Koh, Jong Sung ; Lee, Byung Il</creator><creatorcontrib>Lee, Sang Jae ; Choi, Jang‐Sik ; Han, Byeong‐Gu ; Kim, Hyoun Sook ; Song, Ho‐Juhn ; Lee, Jaekyoo ; Nam, Seungyoon ; Goh, Sung‐Ho ; Kim, Jung‐Ho ; Koh, Jong Sung ; Lee, Byung Il</creatorcontrib><description>Spleen tyrosine kinase (SYK) is a cytosolic nonreceptor protein tyrosine kinase that mediates key signal transduction pathways following the activation of immune cell receptors. SYK regulates cellular events induced by the B‐cell receptor and Fc receptors with high intrinsic activity. Furthermore, SYK has been regarded as an attractive target for the treatment of autoimmune diseases and cancers. Here, we report the crystal structures of SYK in complex with seven newly developed inhibitors (G206, G207, O178, O194, O259, O272, and O282) to provide structural insights into which substituents of the inhibitors and binding regions of SYK are essential for lead compound optimization. Our kinase inhibitors exhibited high inhibitory activities against SYK, with half‐maximal inhibitory concentrations (IC50) of approximately 0.7–33 nm, but they showed dissimilar inhibitory activities against KDR, RET, JAK2, JAK3, and FLT3. Among the seven SYK inhibitors, O272 and O282 exhibited highly specific inhibitions against SYK, whereas O194 exhibited strong inhibition of both SYK and FLT3. Three inhibitors (G206, G207, and O178) more efficiently inhibited FLT3 while still substantially inhibiting SYK activity. The binding mode analysis suggested that a highly selective SYK inhibitor can be developed by optimizing the functional groups that facilitate direct interactions with Asn499. Database The atomic coordinates and structure factors for human SYK are in the Protein Data Bank under accession codes 4XG2 (inhibitor‐free form), 4XG3 (G206), 4XG4 (G207), 5GHV (O178), 4XG6 (O194), 4XG7 (O259), 4XG8 (O272), and 4XG9 (O282). Spleen tyrosine kinase (SYK) has been regarded as an attractive target for the treatment of autoimmune diseases and cancers. Our crystal structures of SYK in complex with seven newly developed inhibitors can provide structural insights into which substituents (a, b, and c) of the inhibitors, and binding regions of SYK are essential for lead compound optimization.</description><identifier>ISSN: 1742-464X</identifier><identifier>EISSN: 1742-4658</identifier><identifier>DOI: 10.1111/febs.13831</identifier><identifier>PMID: 27504936</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Cancer therapies ; Crystal structure ; Crystallography, X-Ray ; Drug Design ; drug discovery ; Indazoles - chemistry ; kinase ; Kinases ; Models, Molecular ; Oxazines - chemistry ; Protein Kinase Inhibitors - chemistry ; Protein Kinase Inhibitors - pharmacology ; Pyrazines - chemistry ; Pyridines - chemistry ; Signal transduction ; Spleen ; spleen tyrosine kinase ; Syk Kinase - antagonists &amp; inhibitors ; Syk Kinase - chemistry</subject><ispartof>The FEBS journal, 2016-10, Vol.283 (19), p.3613-3625</ispartof><rights>2016 Federation of European Biochemical Societies</rights><rights>2016 Federation of European Biochemical Societies.</rights><rights>Copyright © 2016 Federation of European Biochemical Societies</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5371-f088863d27c4dce632fa272fa03993319c96cbd20f27440f168b35a97ab525f3</citedby><cites>FETCH-LOGICAL-c5371-f088863d27c4dce632fa272fa03993319c96cbd20f27440f168b35a97ab525f3</cites><orcidid>0000-0002-5366-2900</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ffebs.13831$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ffebs.13831$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27504936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Sang Jae</creatorcontrib><creatorcontrib>Choi, Jang‐Sik</creatorcontrib><creatorcontrib>Han, Byeong‐Gu</creatorcontrib><creatorcontrib>Kim, Hyoun Sook</creatorcontrib><creatorcontrib>Song, Ho‐Juhn</creatorcontrib><creatorcontrib>Lee, Jaekyoo</creatorcontrib><creatorcontrib>Nam, Seungyoon</creatorcontrib><creatorcontrib>Goh, Sung‐Ho</creatorcontrib><creatorcontrib>Kim, Jung‐Ho</creatorcontrib><creatorcontrib>Koh, Jong Sung</creatorcontrib><creatorcontrib>Lee, Byung Il</creatorcontrib><title>Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs</title><title>The FEBS journal</title><addtitle>FEBS J</addtitle><description>Spleen tyrosine kinase (SYK) is a cytosolic nonreceptor protein tyrosine kinase that mediates key signal transduction pathways following the activation of immune cell receptors. SYK regulates cellular events induced by the B‐cell receptor and Fc receptors with high intrinsic activity. Furthermore, SYK has been regarded as an attractive target for the treatment of autoimmune diseases and cancers. Here, we report the crystal structures of SYK in complex with seven newly developed inhibitors (G206, G207, O178, O194, O259, O272, and O282) to provide structural insights into which substituents of the inhibitors and binding regions of SYK are essential for lead compound optimization. Our kinase inhibitors exhibited high inhibitory activities against SYK, with half‐maximal inhibitory concentrations (IC50) of approximately 0.7–33 nm, but they showed dissimilar inhibitory activities against KDR, RET, JAK2, JAK3, and FLT3. Among the seven SYK inhibitors, O272 and O282 exhibited highly specific inhibitions against SYK, whereas O194 exhibited strong inhibition of both SYK and FLT3. Three inhibitors (G206, G207, and O178) more efficiently inhibited FLT3 while still substantially inhibiting SYK activity. The binding mode analysis suggested that a highly selective SYK inhibitor can be developed by optimizing the functional groups that facilitate direct interactions with Asn499. Database The atomic coordinates and structure factors for human SYK are in the Protein Data Bank under accession codes 4XG2 (inhibitor‐free form), 4XG3 (G206), 4XG4 (G207), 5GHV (O178), 4XG6 (O194), 4XG7 (O259), 4XG8 (O272), and 4XG9 (O282). Spleen tyrosine kinase (SYK) has been regarded as an attractive target for the treatment of autoimmune diseases and cancers. Our crystal structures of SYK in complex with seven newly developed inhibitors can provide structural insights into which substituents (a, b, and c) of the inhibitors, and binding regions of SYK are essential for lead compound optimization.</description><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Cancer therapies</subject><subject>Crystal structure</subject><subject>Crystallography, X-Ray</subject><subject>Drug Design</subject><subject>drug discovery</subject><subject>Indazoles - chemistry</subject><subject>kinase</subject><subject>Kinases</subject><subject>Models, Molecular</subject><subject>Oxazines - chemistry</subject><subject>Protein Kinase Inhibitors - chemistry</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Pyrazines - chemistry</subject><subject>Pyridines - chemistry</subject><subject>Signal transduction</subject><subject>Spleen</subject><subject>spleen tyrosine kinase</subject><subject>Syk Kinase - antagonists &amp; inhibitors</subject><subject>Syk Kinase - chemistry</subject><issn>1742-464X</issn><issn>1742-4658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1PFDEYhxuiEUQv_AGmiRdDstDPaccbbEBNSDzAwduk02nZ4my79O2Ae-Q_t-viHjgY26Qfb588Sd8fQkeUnNA6Tr3r4YRyzekeOqBKsJlopH61O4sf--gtwB0hXIq2fYP2mZJEtLw5QE_zvIZiRgwlT7ZM2QFOHsNqdC7iss4JQnT4Z4gGHA4R27Ssb7_wYygLHNODG2t1EfpQUobPO43ZlCHcLgpgnzIeXL3EjdrEEqyJ1tVinm7hHXrtzQju_fN-iG4uL27mX2dX3798m59dzazkis480Vo3fGDKisG6hjNvmKoL4W3LOW1t29h-YMQzJQTxtNE9l6ZVppdMen6IPm21q5zuJwelWwawbhxNdGmCjmquONG1K_-DyjqpVBX9-AK9S1OO9R-VEkIrqhit1PGWsrWdkJ3vVjksTV53lHSbCLtNhN2fCCv84Vk59Us37NC_mVWAboHHMLr1P1Td5cX59Vb6G1d6p9E</recordid><startdate>201610</startdate><enddate>201610</enddate><creator>Lee, Sang Jae</creator><creator>Choi, Jang‐Sik</creator><creator>Han, Byeong‐Gu</creator><creator>Kim, Hyoun Sook</creator><creator>Song, Ho‐Juhn</creator><creator>Lee, Jaekyoo</creator><creator>Nam, Seungyoon</creator><creator>Goh, Sung‐Ho</creator><creator>Kim, Jung‐Ho</creator><creator>Koh, Jong Sung</creator><creator>Lee, Byung Il</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5366-2900</orcidid></search><sort><creationdate>201610</creationdate><title>Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs</title><author>Lee, Sang Jae ; Choi, Jang‐Sik ; Han, Byeong‐Gu ; Kim, Hyoun Sook ; Song, Ho‐Juhn ; Lee, Jaekyoo ; Nam, Seungyoon ; Goh, Sung‐Ho ; Kim, Jung‐Ho ; Koh, Jong Sung ; Lee, Byung Il</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5371-f088863d27c4dce632fa272fa03993319c96cbd20f27440f168b35a97ab525f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Cancer therapies</topic><topic>Crystal structure</topic><topic>Crystallography, X-Ray</topic><topic>Drug Design</topic><topic>drug discovery</topic><topic>Indazoles - chemistry</topic><topic>kinase</topic><topic>Kinases</topic><topic>Models, Molecular</topic><topic>Oxazines - chemistry</topic><topic>Protein Kinase Inhibitors - chemistry</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Pyrazines - chemistry</topic><topic>Pyridines - chemistry</topic><topic>Signal transduction</topic><topic>Spleen</topic><topic>spleen tyrosine kinase</topic><topic>Syk Kinase - antagonists &amp; inhibitors</topic><topic>Syk Kinase - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Sang Jae</creatorcontrib><creatorcontrib>Choi, Jang‐Sik</creatorcontrib><creatorcontrib>Han, Byeong‐Gu</creatorcontrib><creatorcontrib>Kim, Hyoun Sook</creatorcontrib><creatorcontrib>Song, Ho‐Juhn</creatorcontrib><creatorcontrib>Lee, Jaekyoo</creatorcontrib><creatorcontrib>Nam, Seungyoon</creatorcontrib><creatorcontrib>Goh, Sung‐Ho</creatorcontrib><creatorcontrib>Kim, Jung‐Ho</creatorcontrib><creatorcontrib>Koh, Jong Sung</creatorcontrib><creatorcontrib>Lee, Byung Il</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The FEBS journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Sang Jae</au><au>Choi, Jang‐Sik</au><au>Han, Byeong‐Gu</au><au>Kim, Hyoun Sook</au><au>Song, Ho‐Juhn</au><au>Lee, Jaekyoo</au><au>Nam, Seungyoon</au><au>Goh, Sung‐Ho</au><au>Kim, Jung‐Ho</au><au>Koh, Jong Sung</au><au>Lee, Byung Il</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs</atitle><jtitle>The FEBS journal</jtitle><addtitle>FEBS J</addtitle><date>2016-10</date><risdate>2016</risdate><volume>283</volume><issue>19</issue><spage>3613</spage><epage>3625</epage><pages>3613-3625</pages><issn>1742-464X</issn><eissn>1742-4658</eissn><abstract>Spleen tyrosine kinase (SYK) is a cytosolic nonreceptor protein tyrosine kinase that mediates key signal transduction pathways following the activation of immune cell receptors. SYK regulates cellular events induced by the B‐cell receptor and Fc receptors with high intrinsic activity. Furthermore, SYK has been regarded as an attractive target for the treatment of autoimmune diseases and cancers. Here, we report the crystal structures of SYK in complex with seven newly developed inhibitors (G206, G207, O178, O194, O259, O272, and O282) to provide structural insights into which substituents of the inhibitors and binding regions of SYK are essential for lead compound optimization. Our kinase inhibitors exhibited high inhibitory activities against SYK, with half‐maximal inhibitory concentrations (IC50) of approximately 0.7–33 nm, but they showed dissimilar inhibitory activities against KDR, RET, JAK2, JAK3, and FLT3. Among the seven SYK inhibitors, O272 and O282 exhibited highly specific inhibitions against SYK, whereas O194 exhibited strong inhibition of both SYK and FLT3. Three inhibitors (G206, G207, and O178) more efficiently inhibited FLT3 while still substantially inhibiting SYK activity. The binding mode analysis suggested that a highly selective SYK inhibitor can be developed by optimizing the functional groups that facilitate direct interactions with Asn499. Database The atomic coordinates and structure factors for human SYK are in the Protein Data Bank under accession codes 4XG2 (inhibitor‐free form), 4XG3 (G206), 4XG4 (G207), 5GHV (O178), 4XG6 (O194), 4XG7 (O259), 4XG8 (O272), and 4XG9 (O282). Spleen tyrosine kinase (SYK) has been regarded as an attractive target for the treatment of autoimmune diseases and cancers. Our crystal structures of SYK in complex with seven newly developed inhibitors can provide structural insights into which substituents (a, b, and c) of the inhibitors, and binding regions of SYK are essential for lead compound optimization.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>27504936</pmid><doi>10.1111/febs.13831</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-5366-2900</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1742-464X
ispartof The FEBS journal, 2016-10, Vol.283 (19), p.3613-3625
issn 1742-464X
1742-4658
language eng
recordid cdi_proquest_miscellaneous_1837308493
source MEDLINE; Wiley Free Archive; Wiley Blackwell Single Titles; Free Full-Text Journals in Chemistry
subjects Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Cancer therapies
Crystal structure
Crystallography, X-Ray
Drug Design
drug discovery
Indazoles - chemistry
kinase
Kinases
Models, Molecular
Oxazines - chemistry
Protein Kinase Inhibitors - chemistry
Protein Kinase Inhibitors - pharmacology
Pyrazines - chemistry
Pyridines - chemistry
Signal transduction
Spleen
spleen tyrosine kinase
Syk Kinase - antagonists & inhibitors
Syk Kinase - chemistry
title Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T15%3A54%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Crystal%20structures%20of%20spleen%20tyrosine%20kinase%20in%20complex%20with%20novel%20inhibitors:%20structural%20insights%20for%20design%20of%20anticancer%20drugs&rft.jtitle=The%20FEBS%20journal&rft.au=Lee,%20Sang%20Jae&rft.date=2016-10&rft.volume=283&rft.issue=19&rft.spage=3613&rft.epage=3625&rft.pages=3613-3625&rft.issn=1742-464X&rft.eissn=1742-4658&rft_id=info:doi/10.1111/febs.13831&rft_dat=%3Cproquest_cross%3E1837308493%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1844871721&rft_id=info:pmid/27504936&rfr_iscdi=true